A recent study reported that 45.44% of cancer patients exhibit metabolic syndrome (MetS), and 19.23% have CVD; these conditions are components of CKM syndrome and are known to increase the risk of cardiotoxicity when patients are treated with HER2 inhibitors [120]. This evidence concerns the gene ERBB2 and metabolic syndrome.